NOV 0 9 2001

Oey, Jan

From: Jill Schultz [jill.schultz@Covance.Com]
Sent: Friday, November 09, 2001 3:44 PM
To: Jan.Oey@pmusa.com; robin.d.kinser@pmusa.com
Subject: Fwd: Philip Morris Validation Summary Sheets

NNAL Summary.xls

AcN Blood Summary.xls

AcN Exhalate Summary.xls

Nicotine Summary.xls

Cotinine Summary.xls

3-Hydroxycotinine Summary.xls

3-ABP Summary.xls

4-ABP Summary.xls

NDA Plasma Summary.xls

NDA Urine Summary.xls

Caffeine Summary.xls

See attached. Jill

Date: Fri, 09 Nov 2001 14:43:03 -0600
From: "Jill Schultz" <jill.schultz@covance.com>
To: "Jason Walters" <jason.walters@covance.com>,
"Jeffrey Eberhard" <jeffrey.eberhard@covance.com>,
"Keith Phillips" <keithphillips@covance.com>,
"Mark Bentley" <markbentley@covance.com>,
"Mel Feit" <mel.feit@covance.com>,
"Mike Klawikowski" <michael.klawikowski@covance.com>,
"Paul Severin" <paul.severin@covance.com>,
"Phillip Turpin" <phillipturpin@covance.com>,
"Sharon Pochron" <SPOCHRON@covance.com>
Subject: Philip Morris Validation Summary Sheets

Attached are the following validation summary sheets:

NNAL
AcN in blood
AcN in exhalate
Nicotine
Cotinine
3-Hydroxycotinine
3-ABP
4-ABP
Caffeine (137X, 17U, AFMU, 1X, and 17X)

Philip Morris asked that each of the analytical groups review the summary sheets and provide feedback regarding the trend that Philip Morris and consultant have observed (greater percison for less concentrated samples). Please provide your feedback to me by 11/16 via email and I will send one response to Philip Morris. Further discussions may be needed.

Thank you,

Jill

Confidentiality Notice: This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance

Source: https://www.industrydocuments.ucsf.edu/docs/pqcj0001